Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.80 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.80 |
| ▸ | VEGFA | P15692 | 6/20 | 0.80 |
| ▸ | FLT1 | P17948 | 6/20 | 0.80 |
| ▸ | TET3 | O43151 | 1/20 | 0.80 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.80 |
| ▸ | ASPH | Q12797 | 1/20 | 0.80 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.80 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.80 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.80 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.80 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.80 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957055 | 1.00 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL30948567 | 1.00 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL29357486 | 0.89 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL1920738 | 0.89 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL29405970 | 0.89 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL22588827 | 0.87 | EGLN1 (0.81) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL25777345 | 0.86 | EGLN1 (0.73) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL24164807 | 0.85 | EGLN1 (0.72) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL19933514 | 0.85 | EGLN1 (0.72) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL30957053 | 0.85 | EGLN1 (0.72) | EGLN1EGLN3VEGFAFLT1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | AKEBIA THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-113767089-B | Method for producing vardostat intermediate | 株式会社钟化 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024079708-A1 | A PROCESS FOR THE PREPARATION OF VADADUSTAT OR SALTS THEREOF | AMI LIFESCIENCES PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024079708-A1 | A PROCESS FOR THE PREPARATION OF VADADUSTAT OR SALTS THEREOF | AMI LIFESCIENCES PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| CN-113767089-A | Preparation method of vatacostat intermediate | 株式会社钟化 | 2021-12-07 | — | — | CN | disclosed |
| WO-2021117767-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | 田辺三菱製薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | DIMT1, HIF1A, HIF1AN | EGLN1 912/4885EGLN3 516/4885VEGFA 269/4885 |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | EGLN1 1247/4885EGLN3 1117/4885VEGFA 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.